Chief Operating Officer / Chief Scientific Officer
Andrea Sáez provides a strong scientific background complemented by broad experience in regulatory, biotech and venture capital roles. She initiated her academic career with a PhD in Immunology by Pompeu Fabra University followed by a postdoctoral stay at Vall d’Hebron Hospital where she studied and published on the therapeutic benefit of TGFbeta inhibitors in preclinical models of cancer. She gained deep understanding of regulatory affairs and drug development in her role as Scientific and Regulatory Affairs Manager at Asphalion, a leading RA consultancy, after which she became Director of R&D at Pangaea Oncology leading drug discovery projects in alliance with external institutions such as Cancer Research Technologies (UK). Finally, prior to joining Origo Biopharma, Andrea supported biotech investments as Senior Associate at Asabys Partners.